

Felica Cosman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9362003/publications.pdf>

Version: 2024-02-01

115
papers

18,230
citations

38742

50
h-index

24982

109
g-index

117
all docs

117
docs citations

117
times ranked

10383
citing authors

#	ARTICLE	IF	CITATIONS
1	Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial. <i>Osteoporosis International</i> , 2022, 33, 239-250.	3.1	10
2	Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. <i>Advances in Therapy</i> , 2022, 39, 58-74.	2.9	49
3	Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck. <i>Bone</i> , 2022, 157, 116342.	2.9	6
4	Romosozumab and antiresorptive treatment: the importance of treatment sequence. <i>Osteoporosis International</i> , 2022, 33, 1243-1256.	3.1	38
5	Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study. <i>Osteoporosis International</i> , 2022, 33, 1703-1714.	3.1	9
6	Romsozumab for the treatment of postmenopausal osteoporosis. , 2021, , 1827-1833.		0
7	Teriparatide and abaloparatide treatment for osteoporosis. , 2021, , 1757-1769.		0
8	Long-term treatment strategies and goal-directed therapy. , 2021, , 1867-1872.		2
9	Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?. <i>Current Osteoporosis Reports</i> , 2021, 19, 189-205.	3.6	18
10	Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis. <i>Osteoporosis International</i> , 2021, 32, 1879-1888.	3.1	3
11	Romsozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals. <i>JBMR Plus</i> , 2021, 5, e10546.	2.7	3
12	Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 219-225.	2.8	15
13	Abnormal microarchitecture and stiffness in postmenopausal women with isolated osteoporosis at the 1/3 radius. <i>Bone</i> , 2020, 132, 115211.	2.9	6
14	Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3384-3395.	3.6	24
15	Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective?. <i>Osteoporosis International</i> , 2020, 31, 2321-2335.	3.1	16
16	Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVEExtend. <i>Menopause</i> , 2020, 27, 1137-1142.	2.0	5
17	Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. <i>Current Medical Research and Opinion</i> , 2020, 36, 1861-1872.	1.9	12
18	No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients. <i>Bone Reports</i> , 2020, 12, 100253.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture. <i>Endocrine Practice</i> , 2020, 26, 777-786.	2.1	34
20	Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1282-1288.	2.8	30
21	Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis. <i>Osteoporosis International</i> , 2020, 31, 1025-1048.	3.1	68
22	Loading modality and age influence teriparatide-induced bone formation in the human femoral neck. <i>Bone</i> , 2020, 136, 115373.	2.9	5
23	Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1225-1234.	2.8	14
24	T-score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1333-1342.	2.8	32
25	Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2019, 30, 1187-1194.	3.1	25
26	Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1033-1040.	2.8	79
27	The evolving role of anabolic therapy in the treatment of osteoporosis. <i>Current Opinion in Rheumatology</i> , 2019, 31, 376-380.	4.3	12
28	Administration of teriparatide for four years cyclically compared to two years daily in treatment Na ⁺ ve and alendronate treated women. <i>Bone</i> , 2019, 120, 246-253.	2.9	15
29	Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 810-816.	2.8	22
30	Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. <i>Menopause</i> , 2018, 25, 767-771.	2.0	31
31	FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1219-1226.	2.8	108
32	Long-term treatment strategies for postmenopausal osteoporosis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 420-426.	4.3	19
33	Parathyroid hormone and abaloparatide treatment for osteoporosis. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2018, 3, 61-67.	1.4	3
34	ACTIVEExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2949-2957.	3.6	131
35	Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1407-1416.	2.8	56
36	OP0344...Frame study: the foundation effect of rebuilding bone with one year of romosozumab leads to continued lower fracture risk after transition to denosumab., 2018,, .		0

#	ARTICLE	IF	CITATIONS
37	Results of a fracture liaison service on hip fracture patients in an open healthcare system. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 331-334.	2.9	22
38	Unmasking romosozumab: response to comments by Uzoigwe et al.. <i>Osteoporosis International</i> , 2017, 28, 2021-2022.	3.1	1
39	Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 200-210.	3.0	109
40	Spine fracture prevalence in a nationally representative sample of US women and men aged ≥40 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013-2014. <i>Osteoporosis International</i> , 2017, 28, 1857-1866.	3.1	86
41	Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 198-202.	2.8	181
42	Spine fracture prevalence in a nationally representative sample of US women and men aged ≥40 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013-2014—supplementary presentation. <i>Osteoporosis International</i> , 2017, 28, 2319-2320.	3.1	10
43	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 3-10.	2.8	127
44	Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 17-23.	2.8	75
45	Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1518-1526.	2.8	35
46	Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 722.	7.4	618
47	Romosozumab Treatment in Postmenopausal Women with Osteoporosis. <i>New England Journal of Medicine</i> , 2016, 375, 1532-1543.	27.0	1,099
48	Eating disorders, menstrual dysfunction, weight change and DMPA use predict bone density change in college-aged women. <i>Bone</i> , 2016, 84, 113-119.	2.9	15
49	A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates. <i>Osteoporosis International</i> , 2016, 27, 377-386.	3.1	20
50	Effect of Teriparatide on Bone Formation in the Human Femoral Neck. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1498-1505.	3.6	33
51	The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2015, 30, 934-944.	2.8	205
52	Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2769-2776.	3.6	33
53	Abaloparatide: a new anabolic therapy on the horizon. <i>BoneKEy Reports</i> , 2015, 4, 661.	2.7	13
54	Combination therapy for osteoporosis: a reappraisal. <i>BoneKEy Reports</i> , 2014, 3, 518.	2.7	45

#	ARTICLE	IF	CITATIONS
55	Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4546-4554.	3.6	109
56	Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1-23.	2.8	1,424
57	Clinicianâ€™s Guide to Prevention and Treatment of Osteoporosis. <i>Osteoporosis International</i> , 2014, 25, 2359-2381.	3.1	2,549
58	Anabolic and Antiresorptive Therapy for Osteoporosis: Combination and Sequential Approaches. <i>Current Osteoporosis Reports</i> , 2014, 12, 385-395.	3.6	79
59	Goal-directed treatment of osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 433-438.	2.8	54
60	Determinants of stress fracture risk in United States Military Academy cadets. <i>Bone</i> , 2013, 55, 359-366.	2.9	129
61	Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1328-1336.	2.8	76
62	Changes in vitamin D metabolites during teriparatide treatment. <i>Bone</i> , 2012, 50, 1368-1371.	2.9	15
63	The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012, 27, 243-254.	2.8	552
64	Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 702-712.	2.8	26
65	Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture riskâ€”a perspective. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 963-974.	2.8	94
66	Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1â€“34)] in postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 503-511.	2.8	291
67	Fragility fractures of the hip and femur: incidence and patient characteristics. <i>Osteoporosis International</i> , 2010, 21, 399-408.	3.1	239
68	Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2267-2294.	2.8	994
69	Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 151-158.	3.6	168
70	Treatment of Osteoporosis and Prevention of New Fractures: Role of Intravenously Administered Bisphosphonates. <i>Endocrine Practice</i> , 2009, 15, 483-493.	2.1	23
71	Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3772-3780.	3.6	153
72	Retreatment With Teriparatide One Year After the First Teriparatide Course in Patients on Continued Long-Term Alendronate. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1110-1115.	2.8	44

#	ARTICLE	IF	CITATIONS
73	Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. <i>Osteoporosis International</i> , 2008, 19, 529-535.	3.1	45
74	Measuring serum calcium before and after teriparatide treatment: authors'™ response. <i>Osteoporosis International</i> , 2008, 19, 1809-1809.	3.1	0
75	Relationship between growth hormone in vivo bioactivity, the insulin-like growth factor-I system and bone mineral density in young, physically fit men and women. <i>Growth Hormone and IGF Research</i> , 2008, 18, 439-445.	1.1	15
76	Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: The role of comparative studies and implications for future studies. <i>Clinical Therapeutics</i> , 2007, 29, 1116-1127.	2.5	10
77	Vitamin D Economy in Blacks. <i>Journal of Bone and Mineral Research</i> , 2007, 22, V34-V38.	2.8	48
78	Effects Of a One-Month Treatment With PTH(1-34) on Bone Formation on Cancellous, Endocortical, and Periosteal Surfaces of the Human Ilium. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 495-502.	2.8	219
79	Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2007, 356, 1809-1822.	27.0	2,536
80	Relationship Between Bioassayable Growth Hormone, The Insulin-Like Growth Factor-I System and Bone Mineral Density in Men and Women. <i>FASEB Journal</i> , 2007, 21, A1421.	0.5	0
81	Anabolic therapy for osteoporosis: Parathyroid hormone. <i>Current Rheumatology Reports</i> , 2006, 8, 63-69.	4.7	13
82	A Novel Tetracycline Labeling Schedule for Longitudinal Evaluation of the Short-Term Effects of Anabolic Therapy With a Single Iliac Crest Bone Biopsy: Early Actions of Teriparatide. <i>Journal of Bone and Mineral Research</i> , 2005, 21, 366-373.	2.8	248
83	Anabolic therapy for osteoporosis: Parathyroid hormone. <i>Current Osteoporosis Reports</i> , 2005, 3, 143-149.	3.6	16
84	Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate. <i>New England Journal of Medicine</i> , 2005, 353, 566-575.	27.0	245
85	Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. <i>Thrombosis Research</i> , 2005, 116, 1-13.	1.7	84
86	Anabolic therapy for osteoporosis: Parathyroid hormone. <i>Current Osteoporosis Reports</i> , 2005, 3, 143-149.	3.6	0
87	Therapeutic potential of parathyroid hormone. <i>Current Osteoporosis Reports</i> , 2004, 2, 5-11.	3.6	26
88	Selective estrogen-receptor modulators. <i>Clinics in Geriatric Medicine</i> , 2003, 19, 371-379.	2.6	32
89	Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1150-1156.	3.6	228
90	Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 1846-1853.	2.8	580

#	ARTICLE	IF	CITATIONS
91	Parathyroid Hormone Added to Established Hormone Therapy: Effects on Vertebral Fracture and Maintenance of Bone Mass After Parathyroid Hormone Withdrawal. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 925-931.	2.8	294
92	Biochemical Responses of Bone Metabolism to 1,25-Dihydroxyvitamin D Administration in Black and White Women. <i>Osteoporosis International</i> , 2000, 11, 271-277.	3.1	35
93	Parathyroid Hormone as a Therapy for Idiopathic Osteoporosis in Men: Effects on Bone Mineral Density and Bone Markers ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3069-3076.	3.6	331
94	Addition of Alendronate to Ongoing Hormone Replacement Therapy in the Treatment of Osteoporosis: A Randomized, Controlled Clinical Trial ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 3076-3081.	3.6	150
95	Parathyroid Hormone Secretory Response to EDTA-Induced Hypocalcemia in Black and White Premenopausal Women. <i>Calcified Tissue International</i> , 1999, 65, 257-261.	3.1	13
96	Alendronate Does Not Block the Anabolic Effect of PTH in Postmenopausal Osteoporotic Women. <i>Journal of Bone and Mineral Research</i> , 1998, 13, 1051-1055.	2.8	108
97	Is Parathyroid Hormone a Therapeutic Option for Osteoporosis? A Review of the Clinical Evidence. <i>Calcified Tissue International</i> , 1998, 62, 475-480.	3.1	91
98	Parathyroid Responsivity in Postmenopausal Women with Osteoporosis During Treatment with Parathyroid Hormone ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 788-790.	3.6	14
99	Bone Mass and Vitamin D Deficiency in Adults with Advanced Cystic Fibrosis Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 157, 1892-1899.	5.6	167
100	Fracture history and bone loss in patients with MS. <i>Neurology</i> , 1998, 51, 1161-1165.	1.1	171
101	Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. <i>Lancet</i> , The, 1997, 350, 550-555.	13.7	713
102	Histomorphometric Assessment of Bone Mass, Structure, and Remodeling: A Comparison Between Healthy Black and White Premenopausal Women. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 948-957.	2.8	78
103	Resistance to Bone Resorbing Effects of PTH in Black Women. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 958-966.	2.8	173
104	Bone density change and biochemical indices of skeletal turnover. <i>Calcified Tissue International</i> , 1996, 58, 236-243.	3.1	95
105	Bone Density Change and Biochemical Indices of Skeletal Turnover. <i>Calcified Tissue International</i> , 1996, 58, 236-243.	3.1	9
106	Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: Effects of estrogen therapy. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 594-600.	2.8	8
107	Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 1393-1399.	2.8	127
108	Effects of estrogen on response to edetic acid infusion in postmenopausal osteoporotic women.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 78, 939-943.	3.6	39

#	ARTICLE	IF	CITATIONS
109	High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. <i>Journal of Bone and Mineral Research</i> , 1994, 9, 1097-1105.	2.8	129
110	Relationships between quantitative histological measurements and noninvasive assessments of bone mass. <i>Bone</i> , 1992, 13, 237-242.	2.9	42
111	Comparative assessment of bone mineral density of the forearm using single photon and dual X-ray absorptiometry. <i>Calcified Tissue International</i> , 1992, 51, 352-355.	3.1	25
112	Bone mass and body composition in normal women. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 55-63.	2.8	199
113	Radiographic absorptiometry: A simple method for determination of bone mass. <i>Osteoporosis International</i> , 1991, 2, 34-38.	3.1	117
114	Parathyroid Hormone-(1-34) [PTH-(1-34)]: Demonstration of Suppression of Endogenous Secretion Using Immunoradiometric Intact PTH-(1-84) Assay*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 73, 1345-1351.	3.6	52
115	Hypercalcaemia causing declining cognitive function in a head injured patient. <i>Brain Injury</i> , 1989, 3, 315-318.	1.2	2